0001388325-26-000014.txt : 20260427 0001388325-26-000014.hdr.sgml : 20260427 20260427164916 ACCESSION NUMBER: 0001388325-26-000014 CONFORMED SUBMISSION TYPE: SCHEDULE 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92424 FILM NUMBER: 26901745 BUSINESS ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-262-7002 MAIL ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Novo Holdings A/S CENTRAL INDEX KEY: 0001388325 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13D/A BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: TUBORG HAVNEVEJ 19 CITY: HELLERUP PROVINCE COUNTRY: G7 ZIP: 2900 BUSINESS PHONE: 45 8824 8824 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: TUBORG HAVNEVEJ 19 CITY: HELLERUP PROVINCE COUNTRY: G7 ZIP: 2900 FORMER COMPANY: FORMER CONFORMED NAME: Novo A/S DATE OF NAME CHANGE: 20070130 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001193125-21-102332 0001388325 XXXXXXXX LIVE 6 Common Stock, par value $0.0001 per share 04/23/2026 false 0001710072 28036F105 Edgewise Therapeutics, Inc.
1715 38th St. Boulder CO 80301
Barbara Fiorini 45 3527 6592 Novo Holdings A/S Tuborg Havnevej 19 Hellerup G7 DK-2900 0001388325 N Novo Holdings A/S WC N G7 5350000.00 0.00 5350000.00 0.00 5350000.00 N 4.9 CO Common Stock, par value $0.0001 per share Edgewise Therapeutics, Inc. 1715 38th St. Boulder CO 80301 This Amendment No. 6 (this "Amendment No. 6" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on March 31, 2021, and amended on September 16, 2022, September 30, 2022, June 28, 2023, January 25, 2024 and September 23, 2024 (as amended, the "Statement") by the Reporting Person. This Amendment No. 6 is being filed to report the dilution of the Reporting Person's beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Person. Unless otherwise defined herein, capitalized terms used in this Amendment No. 6 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. Novo Holdings A/S beneficially owns 5,350,000 shares of common stock representing approximately 4.98% of the Issuer's outstanding shares of common stock, based upon 107,532,173 shares of common stock outstanding as of April 9, 2026, as reported in the Issuer's definitive proxy statement, filed with the SEC on April 23, 2026. Due to field limitations of the EDGAR filing system, the percentage listed in Row 13 of the Reporting Person's cover page has been rounded down to 4.9%. Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares. Novo Holdings A/S has not effected any transactions in the Issuer's common stock within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuer's common stock within the past 60 days. Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares. The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock on April 23, 2026. Exhibit 99.1 Schedule I Novo Holdings A/S /s/ Barbara Fiorini By Barbara Fiorini, General Counsel, Finance & Operations 04/27/2026 EX-99.1 2 ex-99-04272026_080415.htm SCHEDULE I ex-99-04272026_080415.htm


EXHIBIT 99.1


SCHEDULE I


Information regarding each director and executive officer of both Novo Holdings A/S and the Novo Nordisk Foundation is set forth below.


Novo Holdings A/S


Name, Title

Address

Principal Occupation

Citizenship

Lars Green,

Chair of the Board

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

Denmark

Steen Riisgaard

Co Vice Chair of the Board

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

Denmark

Britt Meelby Jensen

Vice Chair of the Board

Tuborg Havnevej 19

2900 Hellerup

Denmark

Chief Executive Officer,

Ambu A/S

Denmark

Torsten Sløk

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Chief Economist of Apollo Global Management

USA

Denmark

Nirmal Prabhakar Narvekar

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

CEO of Harvard Management Company

USA

Jun Sung Kim

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Head of the endowment fund for the National University of Singapore, and main board member of Samsung Electronics, Korea

Singapore

Francis Michael Cyprian Cuss

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Biopharmaceutical Consultant

USA

United Kingdom

Viviane Monges

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

France

Susanne Antonie Schaffert

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

Germany

Kasim Kutay

Chief Executive Officer

Tuborg Havnevej 19

2900 Hellerup

Denmark

Chief Executive Officer,

Novo Holdings A/S

United Kingdom

Nigel Kevin Govett

Chief Financial Officer

Tuborg Havnevej 19

2900 Hellerup

Denmark

Chief Financial Officer,

Novo Holdings A/S

United Kingdom







Novo Nordisk Foundation

Name, Title

Address

Principal Occupation

Citizenship

Lars Rebien Sørensen

Chair of the Board

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

Denmark

Lars Henrik Munch

Vice Chair of the Board

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

Denmark

Steen Riisgaard

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

Denmark

Lars Green

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professional Board Director

Denmark

Barbara Casadei

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

British Heart Foundation Professor of Cardiovascular Medicine, Honorary Consultant Cardiologist, and Head of the National Heart and Lung Institute at Imperial College London

Italy

Nana Bule Sejbaek

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Operating Advisor,

Goldman Sachs Asset Management and Professional Board Director

Denmark

Christopher Ashby Voigt

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Professor of Advanced Biotechnology and Department Head in Biological Engineering, Massachusetts Institute of Technology (MIT)

USA

Mads Boritz Grøn

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Quality Auditor,

Novo Nordisk A/S

Denmark

Ole Jakob Müller

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Senior Environmental Specialist,

Novonesis

Denmark

Stig Strøbaek

Board Director

Tuborg Havnevej 19

2900 Hellerup

Denmark

Electrician,

Novo Nordisk A/S

Denmark

Mads Krogsgaard Thomsen

Chief Executive Officer

Tuborg Havnevej 19

2900 Hellerup

Denmark

Chief Executive Officer,

Novo Nordisk Foundation

Denmark